Patients with abnormal Pap smear are referred for colposcopy to screen for presence of cervical cancer.
Colposcopic exam should include inspection of the transformation zone, definition of the extent of the lesion and biopsy of the most abnormal area for tissue diagnosis.
The earliest stages of cervical carcinoma are generally asymptomatic.
Watery vaginal discharge, postcoital or postmenopausal bleeding, intermittent spotting, or abdominal pain may be present and is usually unrecognized by the patient.
Preliminary results of a single-arm, open-label, phase II trial demonstrated the efficacy of a combination regimen comprising toripalimab, bevacizumab, and platinum-based chemotherapy for women with refractory, recurrent, or metastatic cervical cancer.
Patients with brain metastasis from gynaecologic cancers often present with an advanced stage disease and have had at least one prior recurrence, according to a study. In addition, the presence of an extracranial disease is common at the time of brain metastasis diagnosis.
For women with cervical cancer who are undergoing radical hysterectomy, preoperative tobacco use and prolonged catheterization appear to contribute to an increased risk of developing postoperative catheter-associated urinary tract infections (UTIs), as reported in a study.
The three-drug regimen consisting of topotecan, paclitaxel, and bevacizumab prolongs progression-free survival in women with recurrent high-grade neuroendocrine carcinoma of the cervix, as shown in a study.
Patients with early-stage cervical usual-type adenocarcinoma and adenosquamous carcinoma who undergo minimally invasive radical hysterectomy (RH) appear to have comparable survival outcomes as their counterparts who receive open RH, according to a study.
Undergoing a minimally invasive radical hysterectomy leads to worse survival outcomes compared with open surgery in patients with early cervical cancer, according to final results of the LACC trial presented at SGO 2022.
New drug applications approved by US FDA as of 16 -30 September 2021 which
includes New Molecular Entities (NMEs) and new biologics. It does not
include Tentative Approvals. Supplemental approvals may have occurred
since the original approval date.
Adding pembrolizumab to chemotherapy with or without bevacizumab significantly extends overall survival (OS) by 8 months in women with recurrent, persistent or metastatic cervical cancer, according to the KEYNOTE-826 study presented at ESMO 2021.
Recurrent implantation failure (RIF) refers to the failure to achieve a clinical pregnancy after three in vitro fertilization (IVF) attempts with at least four good-quality embryos. RIF leaves couples frustrated and desperate for answers and is challenging for clinicians to handle, compounded by the impact of the COVID-19 pandemic restrictions. Two experts, Dr Ameet Patki, Medical Director of Fertility Associates Mumbai and Hon Assoc Prof at KJ Somaiya Medical College & Hospital, India, and Dr Prakash Mayandi, Metro IVF Fertility Centre, Kuala Lumpur, Malaysia, weigh in with their views on managing RIF during the COVID-19 pandemic.